Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | May 2025

Immune checkpoint inhibitors continue to dominate the treatment of non-small-cell lung cancer (NSCLC), while biomarker-based approaches are driving increasing patient segmentation. In 2024, Imfinzi and Alecensa gained label expansions into the resectable early-stage NSCLC space. Additionally, Opdivo plus chemotherapy gained FDA approval for perioperative (neoadjuvant then adjuvant) use in this setting. The metastatic setting also saw new entrants to the space, with the approval of new biomarker-targeted agents: Bizengri for NRG1-mutated NSCLC, and Ensacove for NSCLC with ALK mutations. Additionally, Tecentriq Hybreza, a subcutaneous formulation of Tecentriq, was also approved in all adult indications approved for Tecentriq, including NSCLC. These approvals, against the backdrop of numerous existing agents in the NSCLC space, provide medical oncologists with an ever-increasing array of treatment options.

Questions answered

• What are the treatment rates for NSCLC in the various settings and lines of therapy?
• What are the rates of testing for different biomarkers, and what is the uptake of key biomarker-driven therapies?
• How are new therapy entrants to the NSCLC market performing relative to existing therapies?
• What do surveyed physicians consider the main drivers of and key obstacles to the uptake of select therapies?

Product description

Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

• Understand the treatment landscape for a disease and how physicians make prescribing decisions.
• Evaluate the drivers and obstacles that influence treatment selection.
• Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.

Primary research: Survey of 102 U.S. medical oncologists in the United States fielded during February 24 to March 7, 2025.

Key drugs covered: Alecensa, Enhertu, Gavreto, Imfinzi, Imjudo, Keytruda, Krazati, Libtayo, Lumakras, Opdivo, Retevmo, Rybrevant, Tabrecta, Tagrisso, Tecentriq, Tecentriq Hybreza, Tepmetko, Yervoy.